BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Kyverna Nets Another $85M to Propel Lead Autoimmune Asset

  The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.

  January 26, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Government Flies White Flag on Vaccine Mandate for Businesses

  The U.S. Supreme Court blocked the mandate earlier this month, stating that OSHA had overstepped its authority.

  January 26, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Incyte Withdraws Lymphoma Drug in “Business Decision”

  Incyte’s decision follows consultation with the FDA, where it decided that it could not support any confirmatory studies that might be required in the future given the limited time frame.

  January 26, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Cortexyme Crashes as Key Alzheimer’s Asset Hit with Clinical Hold

  Cortexyme said it plans to provide additional updates pending further talks with the FDA.

  January 26, 2022

   · 

  3 min read

   · 

  Jill Gartz
• 

  Drug Development

  Two Early CRs Put Vaccinex Ahead in Head and Neck Cancer

  Vaccinex announced positive interim response data in a Phase Ib study assessing pepinemab in combination with Merck’s vaunted checkpoint inhibitor, Keytruda.

  January 26, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Pourhassan Out as CytoDyn Seeks Experience to Commercialize Leronlimab

  The company’s focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.

  January 26, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Gilead Combo Therapy Hit with FDA Hold Over Serious Adverse Events

  The FDA placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected adverse events.

  January 26, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  How to Negotiate if Lowballed in a Job Offer

  There are ways to negotiate a better starting salary if an employer lowballs you. Here are two of the most effective ways of going about it.

  January 26, 2022

   · 

  4 min read

   · 

  Brandi Marcene
• 

  Policy

  About 35% of People Who Received Placebo in Vaccine Trials Report Side Effects and More COVID-19 News

  Much has been made about the side effects of the COVID-19 vaccines, but a new study found a startlingly high number of adverse events associated with people who received placebos in clinical trials.

  January 26, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Global Roundup: Norway’s Cytovation Snags $20 Million in a Series A

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  January 26, 2022

   · 

  6 min read

   · 

  Alex Keown